Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
(SUNPHARMA)
XNSE:SUNPHARMA, XBOM:SUNPHARMA
Sun Pharmaceuticals Industries Ltd Q1FY25; 43% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Sun Pharmaceuticals Industries Ltd Q4FY24; 34% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Sun Pharmaceuticals Industries Ltd Q3FY24; 17% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Sun Pharmaceuticals Industries Ltd Q2FY24; 6% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Sun Pharmaceuticals Industries Ltd Q1FY24; 4% fall in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUNPHARMA) Q4 FY23 Earnings Concall Transcript
SUN PHARMACEUTICAL INDUSTRIES LIMITED (NSE : SUNPHARMA) Q4 FY23 Earnings Concall dated May. 26, 2023. Corporate Participants: Abhishek Sharma -- Head of
Sun Pharmaceuticals Ltd Q4FY23 results out, revenue grows by 16%
Sun Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹10,931 Crore, up from ₹9,447 Crore year on year depicting a growth
Sun Pharmaceutical Q3FY23; 3% Growth in Profits
Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions
Sun Pharmaceutical Industries Limited (SUNPHARMA) Q3 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY23 Earnings Concall dated Jan. 31, 2023 Corporate Participants: Abhishek Sharma -- Head of Investor Relations and
Sun Pharmaceutical Industries Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:46] Tushar Manudhane of Motilal Oswal asked about
Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Q2 FY23 Earnings Concall dated Nov. 01, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip S.
Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in
Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Ltd (NSE:SUNPHARMA) Q1 FY23 Earnings Concall dated Jul. 29, 2022 Corporate Participants: Nimish Desai -- Investor Relations Dilip Shanghvi
Sun Pharmaceuticals Industries Ltd. Q4 FY 2022 Research Summary
Overview Sun Pharmaceutical Industries Limited is an Indian pharmaceutical company. The headquarters is situated in Mumbai, Maharashtra. It was incorporated in 1983.
Sun Pharma Research Tear Sheet Q3 FY 2022
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company. The company was incorporated in 1983. It has its headquarter in Mumbai, Maharashtra India. The company
Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q3 FY22 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY22 Earnings Concall dated Jan. 31, 2022 Corporate Participants: Nimish Desai -- Head of Investor Relations Dilip
Infographic: Key highlights from Sun Pharma Q3 2022 earnings results
Sun Pharmaceutical Industries (NSE: SUNPHARMA) reported its third-quarter 2022 earnings results today. The company reported consolidated revenue of ₹10,295 crores with a growth of
Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY22 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Q2 FY22 Earnings Call dated Nov. 02, 2021 Corporate Participants: Nimish Desai -- Head-Investor Relations Dilip Shanghvi --
Key highlights from Sun Pharma Q2 2022 earnings results
Sun Pharmaceutical Industries (NSE: SUNPHARMA) reported its second-quarter 2022 earnings results today. The company reported consolidated revenue of ₹98.4 billion with a